Scientific Affairs Manager

Vincent Plassat

The Truths and Myths of Oral Lipid-Based Drug Delivery Systems
Friday, February 16, 2018
With the increase of molecules in development classified by the DCS as Class II and Class IV, simple formulation approaches like tablets, or powder in a capsule, can lead to suboptimal patient outcomes due to poor oral ... read more
Bringing Poorly Soluble Molecules to Market with Bioavailability Enhancement Technologies
Wednesday, June 15, 2016
According to the popularly cited study from Tufts Center for the Study of Drug Development, it costs $2.6 billion to receive a drug approval.1 Despite the increased investments and revolutionary therapies brought to market... read more